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Abstract objectives Diagnosis of pleural tuberculosis (PT) is still a challenge, particularly in resource-
constrained settings. Alternative diagnostic tools are needed. We aimed at evaluating the utility of
Clinical Prediction Rules (CPRs) for diagnosis of pleural tuberculosis in Peru.
methods We identified CPRs for diagnosis of PT through a structured literature search. CPRs using
high-complexity tests, as defined by the FDA, were excluded. We applied the identified CPRs to
patients with pleural exudates attending two third-level hospitals in Lima, Peru, a setting with high
incidence of tuberculosis. Besides pleural fluid analysis, patients underwent closed pleural biopsy for
reaching a final diagnosis through combining microbiological and histopathological criteria. We
evaluated the performance of the CPRs against this composite reference standard using classic
indicators of diagnostic test validity.
results We found 15 eligible CPRs, of which 12 could be validated. Most included ADA, age,
lymphocyte proportion and protein in pleural fluid as predictive findings. A total of 259 patients were
included for their validation, of which 176 (67%) had PT and 50 (19%) malignant pleural effusion.
The overall accuracy of the CPRs varied from 41% to 86%. Two had a positive likelihood ratio (LR)
above 10, but none a negative LR below 0.1. ADA alone at a cut-off of ≥40 IU attained 87%
diagnostic accuracy and had a positive LR of 6.6 and a negative LR of 0.2.
conclusion Many CPRs for PT are available. In addition to ADA alone, none of them contributes
significantly to diagnosis of PT.
keywords score, adenosine deaminase activity, pleural tuberculosis, Mycobacterium tuberculosis
Introduction
Diagnosis of pleural tuberculosis (PT) is a challenge, par-
ticularly in resource-constrained settings. The occurrence
of pleural exudates raises clinical suspicion of this condi-
tion and patients’ pleural fluids are usually evaluated for
the presence of acid-fast bacilli (AFB) through Ziehl–
Neelsen staining, for malignant cells through haema-
toxylin–eosin staining and through Gram examination
for common bacteria. However, in a large proportion of
cases, these tests do not lead to a diagnosis, amongst
others because the presence of the tuberculous bacilli in
pleural fluid specimens is scarce. Additionally, the diag-
nostic contribution of molecular techniques, when avail-
able, is only modest [1]. Invasive procedures, such as
closed pleural biopsy and thoracoscopy, are then recom-
mended. These can establish the diagnosis in most cases,
but come at the risk of complications, require high-level
expertise and equipment and have an elevated cost [2].
Clinical prediction rules (CPRs), or ‘scores’, have been
developed to contribute to the diagnosis of PT. They
combine several clinical signs or symptoms and/or labora-
tory tests as predictors and could inform clinical deci-
sion-making [3]. However, they need to be locally
validated before implementation. This validation is usu-
ally performed through the evaluation of the standard
indicators of diagnostic performance (sensitivity, speci-
ficity, predictive values and areas under the ROC curve
(AUC)) against a reference diagnostic standard.
Meanwhile, the diagnostic utility of Adenosine deami-
nase activity (ADA) for PT continues to be controversial,
but some recent publications support its use [4, 5]. It has
been advocated as helpful in low-to-medium incidence
settings [6], although not considered in the clinical guide-
lines of these countries [7]. In contrast, it is included in
guidelines for diagnosis of PT in high-incidence Latin
American countries [8]. Its utility, compared to that of
CPRs, has still to be evaluated.
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Our aim was to identify existing CPRs for the diagno-
sis of PT, to determine their performance in patients with
pleural exudates in Peru and to evaluate their clinical
utility in relation to ADA.
Materials and methods
Identification of the CPRs for the diagnosis of PT
We performed literature searches in MEDLINE and
LILACs to retrieve CPRs for PT. For the MEDLINE
search, we followed the procedures suggested by Ingui
et al., prioritising sensitivity [9] with some modifications
and adding the Mesh terms related to ‘tuberculosis’ and
to ‘pleural’, both as MeSh terms and as text. The final
search strategy was ((((‘Sensitivity and Specificity’[Mesh])
OR (‘Diagnosis’[Mesh] OR ‘diagnosis’[Subheading] OR
‘Early Diagnosis’[Mesh] OR ‘Diagnosis, Differen-
tial’[Mesh] OR ‘Clinical Laboratory Techniques’[Mesh])))
AND ((‘Tuberculosis’[Mesh]) OR ‘Mycobacterium tuber-
culosis’[Mesh])) AND ((‘Pleurisy’[Mesh]) OR (‘Pleura’[-
Mesh] OR ‘Empyema, Pleural’[Mesh] OR ‘Tuberculosis,
Pleural’[Mesh] OR ‘Pleural Effusion’[Mesh] OR ‘Pleural
Diseases’[Mesh] OR ‘Empyema, Tuberculous’[Mesh])).
The search was limited to humans and articles published
until June 2016. We searched LILACs using (pleural OR
derrame) AND tuberculosis, applying the same limits.
We manually searched the ‘related articles’ displayed in
PubMed and the references of the selected retrieved papers
for additional CPRs. Two researchers (LS and AS),
screened the abstracts of the retrieved papers and indepen-
dently selected the publications on CPRs to be included.
Discrepancies were solved by consensus. The inclusion cri-
teria were as follows: Clinical Prediction Rules (defined as
a combination of signs, symptoms and laboratory tests
that jointly interpreted lead to a clinical decision) [10] and
having PT as an outcome to be predicted. We excluded
from subsequent evaluation CPRs derived for specific
groups, such as children, HIV positive or inmuno-compro-
mised patients. We also excluded CPRs that included as
predictive findings ‘high-complexity tests’ as defined by
the FDA0s CLIA (clinical laboratory improvement amend-
ments) [11]. These are, amongst others, molecular meth-
ods, interferon-gamma release assays, lysozyme
determinations and antibody tests for M. tuberculosis,
which are not normally available in hospital laboratories,
even at referral level, in low-middle income countries.
Setting, patients and clinical procedures
We performed the validation of the CPRs in patients
attending Hospital Nacional Cayetano Heredia and
Hospital Nacional Hipolito Unanue, third-level hospitals
in Lima, Peru, a Latin American country with a concen-
trated HIV epidemic and a high incidence (120/105) of
tuberculosis. The sample size needed was calculated
based on 90% power to detect an increase of 10% in the
overall accuracy of the evaluated CPRs compared to
ADA determination, for which we assumed a baseline
accuracy of 75%. Allowing for 10% of non-evaluable
cases, the required number of participants was 190.
From October 2009 to February 2012, all new adult
patients that attended the internal medicine wards of
these hospitals and had pleural effusion according to
chest X-ray or ultrasound were screened with Light’s cri-
teria [12] for distinguishing between exudates and transu-
dates. Patients with exudates were referred to the
neumology units for inclusion in the study.
After giving informed consent, demographic and clini-
cal information was collected through direct interviews
and physical examination. Mycobacterial culture in
Lowenstein-Jensen media and papanicolaou was per-
formed on sputum samples of all patients. Pleural aspi-
rates were obtained, and patients with hemothorax or
grossly turbid empyemas were excluded from further
study, as their management required therapeutic surgical
procedures rather than diagnosis. Pleural fluid specimens
were sent for determination of cell count and differential,
glucose, lactate dehidrogenase, protein, ADA, Ziehl–
Neelsen staining, cultures for mycobacteria in Ogawa
and Mycobacterial Growth Indicator Tube (MGIT)
media, PCR for M. tuberculosis and cytology for malig-
nant cells. Trained neumologists performed on all
patients a closed pleural biopsy with Abrams needle
according to standard procedures [13], and the pleural
tissue was sent for histopathological examination by cer-
tified pathologists and for culture in MGIT if tissue quan-
tity sufficed. Specific complementary tests performed
when indicated included culture in Sabouread media for
fungal infections and immunohistochemistry for connec-
tive tissue diseases amongst others. All laboratory results
were promptly communicated to the treating physicians,
who remained in charge for the subsequent management
of the patients.
Diagnostic classification
We classified the patients into four diagnostic categories:
• Pleural Tuberculosis: our reference standard was posi-
tive AFB smear or positivity for M. tuberculosis in
any of the culture media or positive PCR for M. tu-
berculosis in pleural fluid or tissue; or presence of
caseating granulomas in the histopathology; or com-
patible histopathological results (lymphocytic
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infiltration, unspecific granulomas, fibrosis) followed
by resolution of the effusion and symptoms within the
3 months after initiation of antituberculous therapy.
• Malignant pleural exudate: the presence of malignant
cells in the pleural fluid or biopsy
• Other specific pleurisies (connective tissue diseases,
fungal infections and other conditions diagnosed
through histopathology or specific complementary
tests).
• Pleural exudate of unknown cause: patients for whom
no definite diagnosis could be established.
Data analysis
Each withheld CPR was applied to every patient. For
CPRs derived to differentiate PT from other conditions,
the diagnostic categories ‘malignant pleural effusion’ and
‘other specific pleurisies’ were jointly considered ‘Not
PT’. For CPRs designed to differentiate PT from malig-
nant pleural exudates, the diagnostic category ‘other
causes’ were excluded from the analysis.
In both situations, patients with two coexisting aetiolo-
gies for the pleural exudate and those with pleural exu-
dates of unknown cause were excluded from the analysis.
We compared the results obtained through the CPRs
with our reference standard for PT to calculate their sen-
sitivity, specificity, predictive values, likelihood ratios
and, for the CPRs based on scoring systems, the areas
under their ROC curve (AUC)s. We did the same for
ADA at two different cut-off levels: 40 and 60 UI/L. All
statistical analyses were performed with STATA ver. 10.
Ethical aspects
All included patients gave written informed consent for
participation. The ethics committees of Universidad Peru-
ana Cayetano Heredia, Hospital Nacional Cayetano
Heredia, Hospital Nacional Hipolito Unanue and the
Institute of Tropical Medicine, Antwerp approved the
study.
Results
Identified CPRs
We retrieved 2419 publications using our MEDLINE
search strategy and 280 through the LILACs search
(Figure 1). This yielded 25 CPRs and three additional
ones were found through the revision of the references.
Of these, 11 CPRs including one neural network were
excluded because they considered ‘high-complexity’ test
amongst their predictive findings, including one neural
network. Despite the study being performed at two third-
level hospitals, our laboratories were not equipped to
perform C-reactive protein test (CRP), complement acti-
vation products dosage and pleural globulin level
2419 publications 
retrieved in PubMed
280 publications 
retrieved in LILACS
37 selected for full-
text revision
25 CPRs identified
11 CPRs excluded 
due to having  
complex tests as 
predictive findings 
3 CPRs identified 
from the references 
17 CPRs identified
5 elegible CPRs 
included test (s) not 
available in our 
laboratories
12 CPRs evaluated
Figure 1 Clinical Prediction Rules
(CPRs) for Pleural Tuberculosis retrieved
and assessed.
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determination, all classified as moderate complexity tests
by the FDA-CLIA. Neither could we perform the TST on
all patients. For this reason, we could not assess five eligi-
ble CPRs [14–18]. Figure 1 resumes the procedure of
selection of the CPRs.
Table 1 summarises the main characteristics of the 12
CPRs we evaluated [19–30]. Many of them had been
derived in study populations with high incidences of PT.
The most common predictors included were ADA (in 11
CPRs), lymphocyte proportion (in 7), protein in pleural
fluid (in 4) and age (in 6).
Patient characteristics
We evaluated 383 patients for inclusion. Of these, 101
(26.4%) did not consent to participate in the study, five
were lost to follow-up, 12 (3.1%) had pus in the thora-
centesis and in three the procedures of thoracentesis or
pleural biopsy failed. Finally, 262 patients had a com-
plete workup.
Out of them, 176 (67.2%) had PT,140 had microbio-
logical or histopathological confirmation and 36 showed
histopathological signs suggestive of PT and complete res-
olution of symptoms in response to treatment. Fifty
patients had malignant pleural effusion, 12 had other
specific pleurisies such as rheumatoid or fungal pleuritis,
three had concomitant evidence of PT and malignant
pleuritis and 21 (8.1%) had pleural exudates of unknown
cause (Figure 2). Table 2 compares demographic, clinical
and laboratory findings between patients with PT and
not PT (malignant pleural effusion and other specific
pleuritis). Younger age, male gender, former contact with
a patient with tuberculosis, shorter duration of illness,
fever, night sweats and high ADA and protein levels in
pleural fluid were positively associated with PT.
Accuracy of the CPRs
The sensitivity, specificity, predictive values and likeli-
hood ratios for the diagnosis of PT of each of the evalu-
ated CPRs are shown in Table 3. In general, the
sensitivities of the CPRs were substantially lower in our
setting than reported in the original papers, but the speci-
ficities were comparable. While the CPRs designed for
diagnosis of PT attained low sensitivities, Melo’s and
Neves’s had a specificity of 100% and together with Dhe-
da’s, and Demirer’s, attained positive likelihood ratios
above 10. CPRs for differentiation with cancer had
higher sensitivities but did not attain negative likelihood
ratios lower than 0.10. Given the high PT prevalence in
our patients, all CPRs attained high-positive predictive
values (90–100%), but all had negative predictive values
below 70%. ADA alone had the highest overall diagnos-
tic accuracy for diagnosis of TP at a cut-off point of 40
UI/L (87% for diagnosis of PT), with a sensitivity of
86% (95% CI 81–91) and a specificity of 87% (95% CI
77–93) (Table 4).
There were two CPRs expressed as scores, Dheda’s and
Porcel’s (2003). They attained AUC of 0.81 (CI 0.76–
0.90) for diagnosis of PT and 0.91 (CI 0.82–0.95) for
383 patients with pleural 
exudates considered for inclusion
262 patients with
complete workup
101 did not consent to participate
12 with empyema or hemothorax
3 with failed biopsy
50
Malignant
pleural 
effusion
176 
Pleural 
tuberculosis
21 
Exudates of 
unknown
cause
12
Other
pleural 
effusions
5 lost to follow-up
3
Pleural 
tuberculosis 
and 
malignant
effusionFigure 2 Flowchart of patient inclusion
and their final diagnosis, Lima, Peru.
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differentiation between PT and cancer respectively. These
were not significantly different from the AUC for ADA
(0.89, CI 0.81–0.95).
Discussion
We validated 12 clinical prediction rules (CPRs) for diag-
nosis of pleural tuberculosis (PT), most of them derived
during the last decade in countries with moderate or high
incidence of tuberculosis. Our validation series consisted
of patients with pleural exudates, among whom the
prevalence of PT was 67%, not surprising for a country
with a high tuberculosis burden. Some CPRs had very
high specificity but due to their low-to-moderate sensitiv-
ity, attained only modest overall accuracy (the highest at
86%). The Adenosine Deaminase (ADA) test on its own
performed the best according this diagnostic indicator
(87%), due to its better sensitivity and acceptable speci-
ficity (86% and 87% respectively). CPRs added to what
was already achieved by ADA only in terms of specificity,
strengthening the positive likelihood for diagnosis of PT,
but detracting on sensitivity.
Our results constitute the first formal validation of a
set of CPRs for PT, most of which had not been previ-
ously externally validated. We found, as expected, that
they perform less well than in the setting they were devel-
oped. This is common to all kinds of CPRs and is the
reason why it is important to perform their local valida-
tion before application.
We expressly chose not to include CPRs with ‘high-
complexity tests’ among their predictive findings, because
is against the nature of CPRs to use such tests and, more
importantly, because facilities that can perform them are
not common in most high-incidence countries. Still,
research on interferon-gamma release assays (IGRAs)
tests in pleural fluid show promising results [31] for diag-
nosis of TP if combined with other biomarkers. This is
because in isolation it has important limitations: a recent
meta-analysis of 14 studies shows a pooled sensitivity of
72% and a pooled specificity of 78% for the diagnosis of
PT [32]. The assessment of other specific markers of
inflammation due to M. tuberculosis may prove increas-
ingly useful, in line with the physiopathology of pleural
tuberculosis.
However, molecular techniques intended to capture the
presence of bacilli, which are scarce in PT, have low sen-
sitivity [33] and could, at best, be used if and when avail-
able. Other CPRs excluded used lysozyme, antibodies for
M. tuberculosis or citoquines that are definitively of too
high complexity for use in resource-constrained settings
or at peripheral level.
A limitation of this study was that we were not able to
validate five CPRs that included tests of moderate com-
plexity, which could not be performed at our tertiary
Table 2 Demographic, clinical and laboratory findings of patients with pleural tuberculosis (PT) and with other pleurisies, Lima, Peru
PT (n = 176) Not PT (n = 62) P value
Demographic findings and past history
Age in years (median, interquartile range) 37 (34–40) 62 (57– 67) <0.001
Male gender n (%) 124 (70.5) 28 (45.2) 0.001
History of tuberculosis n (%) 19 (10.8) 7 (11.3) 1.00
Contact with a tuberculosis patient n (%) 88 (50.0) 14 (22.6) <0.001
Comorbidity n (%) 53 (30.1) 20 (32.3) 0.75
Clinical findings
Duration of illness in days (median, interquartile range) 35 (31–40) 77 (54–100) <0.001
Cough > 14 days n (%) 61 (34.7) 23 (37.1) 0.76
Expectoration n (%) 75 (42.6) 28 (45.2) 0.77
Fever n (%) 142 (80.7) 28 (45.2) <0.001
Night sweats n (%) 106 (60.2) 21 (33.9) <0.001
Weight loss n (%) 124 (70.5) 43 (69.4) 0.87
Laboratory findings
Leucocyte count in blood (median, interquartile range) 7749 (7529–8376) 8525 (7642–9401) 0.11
HIV infection n (%) 13 (7.7) 3 (5.1) 0.51
White cell count in pleural fluid (/ml) (median, interquartile range) 1949 (1136–2762) 808 (430–1188) 0.11
Lymphocyte percentage in pleural fluid (median, interquartile range) 69 (57–80) 67 (61–74) 0.91
ADA in pleural fluid (U/l) (median, interquartile range) 79 (74–85) 28 (20–36) <0.001
LDH in pleural fluid (U/l) (median, interquartile range) 880 (809–951) 867 (553–1181) 0.90
Protein in pleural fluid (U/l) (median, interquartile range) 5.2 (5.0–5.3) 4.2 (3.8–4.5) <0.001
Glucose in pleural fluid (U/l) (median, interquartile range) 71.8 (68.0–75.6) 79.9 (64.3–95.4) 0.15
1288 © 2017 John Wiley & Sons Ltd
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level hospitals due to laboratory constraints. These tests
were C-reactive protein, complement activation products,
globulin levels in pleural fluid, and TST. The latter test is
a marker of tuberculosis infection, with fluctuating avail-
ability globally, and would probably not be useful in a
setting where more than 50% of the population is posi-
tive [34]. As C-reactive protein is intended to discrimi-
nate PT from bacterial infections, which were not present
in our patient series, it would have scarcely contributed.
A similar situation occurs with pleural globulins and
complement activation products. While pleural globulins
have been associated with TP [35], other infectious con-
ditions such as pneumonia and some neoplastic disorders
like multiple myeloma can significantly raise the level of
globulins in the pleural fluid and currently the trend is to
study the nature of the globulins rather than to assess
them it as a whole [36]. Complement activation products
are most of all useful for diagnosis of lupus and other
connective tissue diseases, when low levels are found,
and less so for TP or cancer diagnosis [37].
The lack of diagnostic thoracoscopy could also be of
concern. Twenty-one (8.1%) patients remained without
definite diagnosis after pleural biopsy and these patients
are, according to current recommendations [38], candi-
dates for thoracoscopy. Notwithstanding, our rate of
undiagnosis is similar to the rate of around 10% reported
in the literature [39]. Finally, of the few patients with
empyema that we excluded from analysis, some could
have been tuberculous pleuritis cases. However, diagnos-
ing PT in the presence of purulent fluid poses no major
diagnostic challenge, as AFB are generally found [40]. At
any rate, empyema calls for surgical intervention. Above
all, this study adds evidence on the utility of ADA in the
diagnostic approach of TP. Currently, only Latin Ameri-
can guidelines consider its use as part of diagnostic rec-
ommendations. An explanation may be that, compared
to other forms of extrapulmonary tuberculosis, pleural
tissue is relatively accessible and that clinicians often
chose to confirm PT through histopathological examina-
tion. However, in countries with high incidence of tuber-
culosis, considerable amounts of resources could be saved
and risks avoided with the use of ADA as a decision-
making tool. Surprisingly, clinical prediction rules do not
or hardly perform better than ADA alone for diagnosis
of PT. Designing CPRs intended to improve on what
ADA already discriminates would be an interesting devel-
opment. In resource-constrained settings, where ADA
determination is not available, Dheda’s CPR, the only
evaluated not including ADA as a predictive finding,
could be an option, despite its moderate (74%) overall
diagnostic accuracy.
In conclusion, we assessed the performance of pub-
lished CPRs for the diagnosis of PT in a country with
high incidence of tuberculosis. We found that they do not
contribute significantly over ADA alone in overall diag-
nostic performance, although some of them improve the
specificity. ADA, an inexpensive, simple and accessible
test, shows a good diagnostic performance and is an
important element in the diagnostic approach to PT.
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